Initial public offering of Nordic Nanovector (NO) on Oslo Stock Exchange — NOK 575 million

Carnegie acted as joint book-runner in the initial public offering of Nordic Nanovector on Oslo Stock Exchange. The Company aspires to become a leading provider of Antibody-Radionuclide-Conjugate clinical solutions, to address major unmet medical needs and to advance cancer care through its innovative therapy programs and patented technologies. March 2015.